960 x 350_41

Diabetes Solutions

Accelerate your diabetes research

With the prevalence of diabetes expected to increase, you need one global partner to accelerate your diabetes research from discovery to post-market. At Q2 Solutions, we offer a complete range of diabetes drug development solutions including central, bioanalytical, ADME and genomic testing and biomarker services – plus support for companion diagnostic studies for personalized medicine.


We also provide support for the full spectrum of diabetic complications: cardiac and vascular pathology due to systemic inflammation; as well as, renal, retinal and neuropathies due to the interactions of numerous cytokines, chemokines and oxidative stress markers. Our diabetes experts work with pharmaceutical scientists to design and support the best panels of unique biomarkers for the diagnosis and treatment of these underserved complications.


Our lab experience includes testing services in support of clinical trials for insulins, GLP-1/glucagon dual-agonists, SGLT2 inhibitors, DPP-4 inhibitors (gliptins), combination therapies and more. See our factsheet to learn more about our broad range of testing services and capabilities for diabetes studies.


We participate in many proficiency and certification programs for endocrine testing, such as:


  • The NLipid Standardization Program
  • CAP Proficiency Scheme
  • We are National Glycohemoglobin Standardization Program (NGSP)
  • CDC a member of the ADA, AACC, IFCC and IDF.


Our industry renowned scientific experts are here to help you navigate today’s increasingly complex drug development programs.

Q2 Solutions offers clinical trial testing services for insulins, GLP-1/glucagon dual-agonists, SGLT2 inhibitors, DPP-4 inhibitors (gliptins), combination therapies and more

Related Thought Leaders Insights

Evaluation of Single Cell RNA Sequencing from FFPE Tissue using 10x Genomics Chromium Gene Expression Flex Assay

Single cell RNA sequencing (scRNA-seq) uncovers tissue heterogeneity by providing gene expression measurements in individual cells within a tissue.  A current limitation of scRNA-seq is the...

Comprehensive Genomic Profiling in FFPE Tissue Sample using TruSight Oncology 500 Assay

Next generation sequencing (NGS)-based comprehensive genomic profiling has emerged as a powerful tool for the large-scale detection of genomic changes. TruSight Oncology 500 (TSO500) Assay employs a...

Single-Cell RNA Profiling of FFPE Tissues

Download this presentation to learn more about a new protocol using Chromium Gene Expression Flex to successfully and reliably conduct single cell RNA sequencing with FFPE tumor biopsy tissues.   ...